key: cord-0741065-ymzhhz0y
authors: Howell, Carrie R.; Zhang, Li; Yi, Nengjun; Mehta, Tapan; Cherrington, Andrea L.; Garvey, W. Timothy
title: Associations between cardiometabolic disease severity, social determinants of health (SDoH) and poor COVID‐19 outcomes
date: 2022-03-29
journal: Obesity (Silver Spring)
DOI: 10.1002/oby.23440
sha: 5bae6814a25b8a85f34cd57720bd8cc9a6da3b8d
doc_id: 741065
cord_uid: ymzhhz0y

OBJECTIVE: Determine the ability of retrospective cardiometabolic disease staging (CMDS) and social determinants of health (SDoH) to predict COVID‐19 outcomes. METHODS: Individual and neighborhood SDoH and CMDS clinical parameters [BMI, glucose, blood pressure, HDL, triglycerides], collected up to 3 years prior to a positive COVID‐19 test, were extracted from the electronic medical record. We used Bayesian logistic regression to model CMDS and SDoH to predict subsequent hospitalization, intensive care unit (ICU) admission, and mortality, and investigated if adding SDoH to the CMDS model improved prediction. Models were cross‐validated and areas under the curve (AUC) were compared. RESULTS: 2,873 patients were identified [mean age: 58 years (SD 13.2), 59% female, 45% Black]. CMDS, insurance status, male sex and higher glucose values were associated with increased odds of all outcomes; area level social vulnerability was associated with increased odds of hospitalization [Odds ratio (OR): 1.84, 95% Confidence Interval (CI): 1.38‐2.45] and ICU admission [OR 1.98, 95 % CI: 1.45‐2.85]. AUC’s improved when SDoH were added to CMDS (p<0.001): hospitalization (AUC 0.78 vs 0.82); ICU admission (AUC 0.77 vs 0.81); mortality (AUC 0.77 vs 0.83). CONCLUSIONS: Retrospective clinical markers of cardiometabolic disease and SDoH were independently predictive of COVID‐19 outcomes in our population.

End stage manifestations of cardiometabolic disease (CMD), such as obesity and type 2 diabetes (T2DM), are associated with poor outcomes in those diagnosed with coronavirus disease 2019 (COVID-19), (1, 2) including increased mortality rates (3) . Cardiometabolic disease begins with insulin resistance, progresses to clinically identifiable high-risk states of metabolic syndrome and prediabetes, and culminates in overt T2DM and cardiovascular disease. Obesity exacerbates insulin resistance and impels progression of this chronic disease process. Not surprisingly, metabolic syndrome (4) and CVD (5) have also been identified as risk factors for poor COVID-19 outcomes.

This suggests that poor prognosis in COVID-19 patients may vary based on an insulin resistance or cardiometabolic continuum, such that patients who have existing sub-optimal metabolic and vascular clinical markers progress to worse outcomes.

Of concern, CMD, obesity, and T2DM disproportionately impact racial and ethnic minorities (6) and those with low socioeconomic status (6) , with marked geographic variations in prevalence rates across the US (7) . A recent study of NHANES data from 2011-2016 estimated diabetes prevalence of 20.4% for non-Hispanic blacks, 22 .1% for Hispanics and 19.1% for Asian adults compared to 12.1% for non-Hispanic whites (8) . Unfavorable neighborhood factors intersect with race and ethnicity in risk, compounding disparities. Black, Hispanic and other minority neighborhoods are often characterized by risk factors such as lack of physical activity resources, poor food options, lower SES and barriers to health care access (9) , all associated with higher diabetes and obesity incidence (10, 11) . Similar disparities have emerged regarding COVID-19 outcomes including racial (12) , social (13) and geographic (13) disparities in incidence and mortality.

Population-based strategies that seek to understand health disparities regarding COVID-19 should consider clinical or biological entities that adversely affect outcomes (i.e., CMD) together with social determinants of health (SDoH), although combined analyses of these factors are rarely performed. Electronic medical records (EMR) of health care systems present an opportunity to integrate SDoH into risk prediction models and stratify populations based on clinical and SDoH parameters. Evaluating how SDoH data can be utilized in the EMR as a tool for disease prevention is an important step to inform clinical care that can address disparities (14) .

To assess contributions of both SDoH and cardiometabolic disease burden on COVID-19 outcomes, we used data retrospectively extracted from the EMR at an academic medical center in

This article is protected by copyright. All rights reserved the Deep South (i.e. Alabama). To quantify cardiometabolic disease burden, we employed a cardiometabolic disease staging (CMDS) score (15, 16) . CMDS incorporates presence and severity of metabolic syndrome traits, reflects severity of insulin resistance, and has been validated to predict risks of diabetes and cardiovascular disease (15, 17) and features a Bayesian logistical regression model highly predictive of future diabetes (16) . Individual and neighborhood level SDoH as well as CMDS data were extracted from medical encounters prior to a positive COVID-19 test. We determined the ability of SDoH and CMDS data to predict subsequent need for hospitalization, intensive care unit (ICU) admission, and mortality once COVID-19 infection occurred, and to investigate the degree to which adding SDoH to the clinical CMDS model improved prediction accuracy.

This article is protected by copyright. All rights reserved

Retrospective longitudinal patient electronic medical record (EMR) data on cardiometabolic markers and SDoH were used to predict subsequent COVID-19 outcomes.

The study population consisted of patients in the UAB Health system, located in Jefferson County, The study was reviewed and approved by the institution's internal review board (IRB); informed consent from study participants was not required.

Primary outcomes of interest were severe COVID-19 outcomes defined as need for hospitalization, admittance to intensive care unit (ICU), or death during hospitalization. Hospitalization was defined as a new hospital admission and a positive COVID-19 PCR in the EMR within 14 days of admission.

An ICU stay was defined as admittance to ICU within initial hospitalization. Death during hospitalization was defined using discharge disposition for hospital admission and a notification of death record clinical event. Outcomes were dichotomized (Yes/No) and modeled separately.

A primary predictor of interest was cardiometabolic disease using risk factors from the cardiometabolic disease staging (CMDS). The CMDS was originally developed as a discrete staging Accepted Article system using presence and severity of metabolic syndrome traits (15) to predict incident diabetes and cardiovascular disease mortality. Risk factors included in the CMDS are body mass index (BMI), glucose, blood pressure, high density lipoprotein cholesterol and triglycerides. Recent CMDS work (16) shows associations between continuous clinical parameters and a robust logistic regression equation for predicting incident diabetes. CMDS scores were generated using the predicted probability equation developed using continuous clinical parameters in previous work (see Table 1 footnote for algorithm). Scores range from 0.0 to 0.99, with higher values indicating a higher probability of developing diabetes within ten years. We also used individual components of the CMDS to develop prediction models to predict severe COVID-19 outcomes. To account for multiple encounters, we used mean clinical values.

Individual social determinants of health: Guided by the 2015 Institute of Medicine report (18), we considered the following individual measures to include: educational attainment, individual income, marital status, employment, and insurance status. Educational attainment, individual income and employment status had either a high level of missingness or were not captured in discrete fields in the EMR, and thus not accessible for analysis. Marital status consisted of married, single, or divorced/widowed. Insurance was categorized as no insurance, public insurance, other, and private insurance.

Neighborhood level social determinants: Patients in the EMR are routinely geocoded and linked to 2010 census tract of residence if address data are available. Neighborhood level data were merged by census tract to describe characteristics of the location where a patient resided. The neighborhood level data included in this analysis are described in the sections below.

Social Vulnerability Index (SVI) (19) . The SVI is a composite index developed using census tract data indicators on 15 social factors, categorized into four main themes: socioeconomic, household composition and disability, minority status and language, and housing and transportation. The index is used to describe social conditions that influence human suffering and financial hardship (social vulnerabilities) for disaster planning and has recently been linked to poor health outcomes (20, 21) . Tracts are assigned a percentile ranking for overall vulnerability. Higher percentile rankings indicate more social vulnerabilities; measures were

This article is protected by copyright. All rights reserved 

Descriptive statistics were used to characterize the study population, overall and by presence of each COVID-19 outcome, respectively. Characteristics by outcome status were compared using parametric (t-tests and chi-square) and non-parametric (Wilcoxon, Fishers exact text) as appropriate.

We used Bayesian logistic regression to test associations between CMDS score, SDoH and COVID-19 outcomes. We then used Bayesian logistic regression to model probability for each binary COVID-19 outcome using individual CMDS components, individual and neighborhood level SDoH, controlling for age, race and gender. Following Gelman et al. (23) , we assigned weakly informative priors (i.e. Cauchy distributions with center 0 and scale 2.5), to the coefficients in the logistic regressions which have the advantage of providing minimal prior information to constrain coefficients in a reasonable range, stabilizing the model fitting, and improving the model prediction performance.

We fit the Bayesian logistic regression models with Cauchy priors by incorporating an approximate

This article is protected by copyright. All rights reserved expectation-maximization algorithm into the usual iteratively weighted least squares in classical logistic regression. We first fitted a Bayesian logistic regression model using only CMDS metabolic syndrome traits, then added individual SDoH (marital status, insurance status), and finally neighborhood SDoH (SVI, rurality, HPSA status). In addition, we ran supplemental models (1) stratified by age due to the severity of COVID-19 in older age adults and (2) using an insurance variable that parsed out recipients of Medicare or Medicaid to approximate individual socioeconomic status in lieu of missing income and education data in the EMR. Results are reported as odds ratios (OR) with 95% confidence intervals (95% CI).

To evaluate predictive performance of the fitted model, we used 10-fold cross-validation with several measures, including area under the curve (AUC), mean squared error (average squared difference between observed and fitted responses), and misclassification (proportion of wrong predicted).

Statistical analysis was performed using R software (version 4.0.3). The model fitting and predictive evaluation were implemented using R function bglm and cv.bh in BhGLM package (https://github.com/nyiuab/BhGLM).

A total of 3,989 patients were identified with a positive PCR and COVID-19 outcome in the institution's EMR and had a previous medical encounter where all clinical data (blood glucose, BMI, blood pressure, high-density lipoprotein cholesterol, and triglycerides) were available (Figure 1 ). We excluded n=548 <35 years of age, leaving an eligible sample of n=3,441 patients. Of these, 568 (16.5%) were missing one or more SDoH measures, resulting in 2,873 patients with complete data for analysis. Patients missing SDoH did not markedly differ by demographic and clinical parameters from those included in analysis (Supplemental Table S1 ). Patients were a mean age of 58 years (SD 13.2), mostly female (59%), 45% were non-Hispanic Black, and most were married (55.4%) ( Table   1 ). About 33% had been hospitalized, 13.6% were admitted to ICU and 4.2% died during hospitalization. About 40% had public insurance and 2% had no insurance. In terms of neighborhood SDoH, most were from metropolitan areas (93.7%), 35% were from areas with high social vulnerability and 31.5% lived in a HPSA census tract. In bivariate analysis comparing characteristics based on COVID-19 outcomes, patients hospitalized, admitted to the ICU or who died were older, more likely to be male, and had higher CMDS scores. Significantly more patients with no or public insurance or lived in census tracts with high levels of social vulnerability experienced poor outcomes. Figure 2 shows odds ratio plots of associations between CMDS score, individual and neighborhood level SDoH and COVID-19 outcomes. Each one standard deviation unit increase in CMDS score was associated with hospitalization (OR 2.00, 95% CI 1.83-2.20), ICU admittance (OR Similarly, adding SDoH to CMDS parameters increased AUCs for both ICU admittance (AUC 0.765 vs 0.808, p<0.05) and mortality (AUC 0.770 vs 0.827, p<0.05). Supplemental Figure S1 shows the receiver operator curves (ROC) for the models shown in Figure 3 . Sensitivity analysis (Supplemental Table S2 ) of the CMDS only model in those with complete lab data regardless of presence of SDoH data (n=3441) produced similar AUCs as the model using the analytical sample (n=2873).

This article is protected by copyright. All rights reserved

In this study using EMR data from an academic medical institution in the Deep South during the COVID-19 pandemic, we found the CMDS score, assessed up to 3 years in advance of COVID-19 infection, was highly associated with increased hospitalizations, ICU admission and mortality. We have also shown for the first time that SDoH, particularly insurance status [none or public] and high area level social vulnerability, independently affect COVID-19 outcomes in addition to cardiometabolic disease burden.

CMDS quantitatively reflects the burden of cardiometabolic disease as assessed by the presence and severity of metabolic syndrome traits. Insulin resistance is central to the pathophysiology of cardiometabolic disease. Our data support the hypothesis that the inflammation, oxidative stress, and endothelial dysfunction that accompany the insulin resistant state are responsible for poor COVID-19 outcomes perhaps by contributing to hyperimmune responses, tissue injury, and a clotting diathesis (24) . Since obesity can accelerate the progression of cardiometabolic disease and its end-stage manifestations include diabetes and hypertension, insulin resistance could constitute a common mechanism explaining the associations of these diseases with poor COVID-19 outcomes.

We originally considered SDoH could affect the biology of COVID-19 infection via adverse effects on the severity of cardiometabolic disease. In this instance, once the contribution of cardiometabolic disease was accounted for, SDoH would no longer be found to independently worsen the course of COVID-19 infection. However, we observed consistent associations with insurance status [none or public] and high area level social vulnerability with severe outcomes independent of metabolic parameters. Thus, adding individual and neighborhood level SDoH to COVID-19 outcome models significantly improved predictability beyond the pathobiological contribution of cardiometabolic disease. It is possible SDoH reflect the embodiment of chronic social related stress via dysregulation of physiological systems, epigenetic modification, and immune and inflammation responses (25) , although further research in this area is needed.

Our results using a CMDS score reflecting cardiometabolic disease risk are consistent with robust associations linking diabetes and obesity with COVID-19 morbidity and mortality (26) and are similar to a study that found a 3-fold increase in mortality and a 4-fold increase in ICU stays among patients hospitalized with COVID-19 who had metabolic syndrome (27) . A recent study employed

This article is protected by copyright. All rights reserved longitudinal medical records to predict risk of mortality among COVID-19 patients (28) using factors deduced with machine learning methods. While a prior diagnosis of diabetes was associated with a 3-fold increase in mortality, metabolic correlates associated with diabetes and cardiometabolic disease (e.g., glucose and HDL) were not investigated; no SDoH were considered. While few studies have capitalized on the rich longitudinal medical records accessible via EMRs, there is advantage in using these data to perform predictive analysis particularly in new disease states for which classical epidemiological cohorts do not exist (29) .

While CMDS score was strongly associated with all outcomes, the models involving individual metabolic components showed varying associations. Elevated glucose levels were associated with severe outcomes, consistent with multiple studies showing strong associations between diabetes (30, 31) and poor glucose control (32, 33). Higher levels of HDL were protective against hospitalization and ICU stays, similar to previous work (34) that investigated if blood metabolites predicted COVID-19 severity progression as well as Zhu et al (33) who found HDL to be protective (OR 0.64, 95% CI 0.50-0.83) from severe symptoms. While the associations found in our study were not surprising, they further reaffirm the ability of the CMDS score in predicting poor COVID-19

outcomes. Unique to our study, we assessed pre-existing cardiometabolic disease clinical parameters collected up to 3 years prior to COVID-19 diagnosis, and, therefore, not acutely affected by the infection per se.

Interestingly, our work did not find independent associations between BMI and severe COVID-19 outcomes which is inconsistent with previous reports associating higher BMI with poor outcomes (35, 36) . We believe this is explained in part by the fact that obesity worsens insulin resistance and cardiometabolic risk and once severity of cardiometabolic disease is considered, obesity loses its significance as an independent risk factor (24) . Previous studies have not examined the full impact of cardiometabolic disease in studies of obesity and COVID-19 outcomes. Further, BMI collected in the clinical setting and captured in the EMR is subject to measurement and data entry errors (37) while biomarkers such as glucose and lipids are not as susceptible to such biases.

increased BMI and poor COVID outcomes (35, 38) . Our analysis was limited to individuals ≥35 with a mean age of 58 years which likely produced differing results for BMI. Indeed, when we looked at bivariate associations in those aged 35-59 in our sample versus those 60 years of age or older (Supplemental Table S3 ), we found higher BMI's and poor COVID-19 outcomes among the younger

This article is protected by copyright. All rights reserved patients, but not older patients. Lastly, methodological issues using BMI such as reverse causation, collider bias, and using BMI as a proxy for adiposity may contribute to our findings (39) .

COVID-19 incidence and outcomes (40, 41) , this is the first investigation to use retrospective metabolic parameters and both individual and neighborhood level SDoH in the EMR to predict subsequent COVID-19 outcomes. We found striking associations between insurance status [none and public] and all outcomes, regardless of how we modeled metabolic parameters (e.g. CMDS score or individual components). We saw a 3-4 fold increased risk for hospitalization and ICU stays among individuals with no or public insurance, with nearly a 6-8 fold increase in risk of mortality, even after controlling for metabolic markers and other SDoH. This is consistent with previous findings showing increases in risk of poor COVID-19 outcomes for both no and public based insurance (42, 43) . Area level indicators have been linked to and several studies have shown higher SVI is associated with higher COVID mortality (44) and incidence (44, 45) . We found an almost twofold increased risk of hospital admission and ICU stays among patients who lived in census tracts with moderate and high social vulnerability, a result not surprising among our local population. The Deep South is a geographic and cultural region in the U.S. that includes the states of Alabama, Georgia, Louisiana, Mississippi, and South Carolina. Alabama is at the core of this geographic region with a higher prevalence of diabetes than the US overall (14.0% vs 10.8%) and persistent disparity by socioeconomic (SES) factors such as education and household income within the state. These socioeconomic and social vulnerability disparities contribute to regional disparities in diabetes prevalence, with a recent study linking higher SVI with increased COVID-19 incidence rates in Alabama (45) . Interestingly, in age stratified models, the addition of SDoH to the model provided more information [increases in AUC] in the younger age models (35-59 years of age) than the 60+ models. While a recent study found that different SDoH were associated with COVID-19 incidence across different age strata (46), our findings warrant further exploration.

Our study has several limitations. Our data was derived from an EMR from a local population which may not be representative of the entire hospital catchment population or national demographics. Generalizing results to other populations should be done with caution. Further, it is possible patients with a positive test were hospitalized later in another local health system introducing bias in outcome ascertainment. In addition, we had a high rate of missing income and education in our discrete EMR fields for which we replaced with area level data such as the SVI to Accepted Article capture socioeconomic status. While these measures may not capture the individual level of SES on outcomes and are prone to the ecological fallacy, such measures can give healthcare systems a 'rough' estimate of SES in the absence of complete data. It is also important to note that insurance status has been used as a proxy for individual socioeconomic status in other studies, particularly when using EMR data where income data is incomplete or nonexistent (47) . While it would have been informative to model insurance based on Medicare vs Medicaid status to infer some degree of income, due to lack of Medicaid expansion in Alabama, only 3% of our sample had Medicaid leaving a narrow category for analysis. While we provide supplementary analyses distinguishing between these two types of insurance, results should be interpreted with caution. Further, while census tract was provided in the EMR in a discrete field, roughly 15% of patients were missing these data and accuracy of geocoding was not available in our dataset. Geocoding is not foolproof; the inability to limit our data to accurately matched census tracts may have introduced some measurement error.

Moving forward, ensuring the accurate and complete capture of SDoH data is imperative to promote health equity, and not inadvertently exacerbate disparities.

In summary, we found cardiometabolic markers collected within 3 years prior to a positive COVID-19 diagnosis among hospitalized patients were predictive subsequent poor outcomes. SDoH improved model predictions and independently contributed to poor outcomes, suggesting effects beyond the pathobiological mechanisms of cardiometabolic disease. Results suggest utilizing prior patient data, including clinical and SDoH, to identify populations at high risk for severe outcomes has potential to help guide treatment, intervention and prevention efforts to improve health and health equity. 

This article is protected by copyright. All rights reserved 

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Association of Obesity with Disease Severity Among Patients with Coronavirus Disease

Diabetes and metabolic syndrome as risk factors for COVID-19

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine

Disparities in the Prevalence of Diagnosed Diabetes -United States

New research directions on disparities in obesity and type 2 diabetes

Prevalence of Diabetes by Race and Ethnicity in the United States

Disparities in diabetes: the nexus of race, poverty, and place

Longitudinal Associations Between Neighborhood Physical and Social Environments and Incident Type 2 Diabetes Mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA)

Undiagnosed Diabetes and Pre-Diabetes in Health Disparities

COVID-19 and African Americans

COVID-19 Emergence and Social and Health Determinants in Colorado: A Rapid Spatial Analysis

Neighborhood Environments and Diabetes Risk and Control

Development of a Weighted Cardiometabolic Disease Staging (CMDS)

System for the Prediction of Future Diabetes

Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study

Poster Abstract #092: CMDS Is a Practical Clinical Estimate of Insulin Resistance in Adults With Overweight/Obesity

Electronic Health Records; Board on Population Health and Public Health Practice; Institute of Medicine. Capturing Social and Behavioral Domains and Measures in Electronic Health Records: Phase 2

Using the Social Vulnerability Index to

Examine Local Disparities in Emergent and Elective Cholecystectomy

Accepted Article This article is protected by copyright. All rights reserved 21

Application of the Social Vulnerability Index for

Identifying Teen Pregnancy Intervention Need in the United States

Health Resource and Service Administration

A weakly informative default prior distribution for logistic and other regression models

Covid-19 & Obesity: Beyond Bmi

Social Determinants of Health: Future Directions for Health Disparities Research

How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit

Mortality Among Adult Black Patients in New Orleans. Diabetes Care

Individualized prediction of COVID-19 adverse outcomes with

Diabetes is a risk factor for the progression and prognosis of COVID-19

Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Accepted Article This article is protected by copyright. All rights reserved 32

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study

J-shaped association between fasting blood glucose levels and COVID-19 severity in patients without diabetes

The metabolic fingerprint of COVID-19 severity

Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study

Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry

Reducing Clinical Noise for

Body Mass Index Measures Due to Unit and Transcription Errors in the Electronic Health Record

Obesity could shift severe COVID-19 disease to younger ages

The 'obesity paradox' may not be a paradox at all

Social determinants of COVID-19 incidence and outcomes: A rapid review

Accepted Article This article is protected by copyright. All rights reserved 41

Clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health

Health Insurance Status and Risk Factors for Poor Outcomes With COVID-19 Among US Health Care Workers: A Cross-Sectional Study

Association of Social and Demographic Factors With COVID-19 Incidence and Death Rates in the US

The Association Between Neighborhood Social Vulnerability and COVID-19 Testing, Positivity, and Incidence in Alabama and Louisiana

Census Tract Patterns and Contextual Social Determinants of Health Associated With COVID-19 in a Hispanic Population From South Texas: A Spatiotemporal Perspective

Associations of Four Community Factors With Longitudinal Change in Hemoglobin A1c Levels in Patients With Type 2 Diabetes

*Cardiometabolic disease staging score (CMDS) calculated using Pr (diabetes) = logit-1

*Sex -0.446*Race), where Pr (diabetes) presents the probability of 10 year incident diabetes for any individual; the function

Sex equals 1 for male and 0 for female, and Race equals 1 for white and 0 for black. CMDS score was calculated for white and black participants only

We would like to thank the COVID-19 Collaborative Outcomes Research Enterprise (CORE), a collaboration involving the institution's COVID-19 Enterprise Research Initiative, Scientific Community of Outcomes Researchers, and the Center for Clinical and Translational Science for facilitating the utilization of institutional data to examine population health outcomes.

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved